Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-055083
Filing Date
2021-11-08
Accepted
2021-11-08 09:01:12
Documents
52
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 2021 Q3 10-Q fbrx-10q_20210930.htm   iXBRL 10-Q 2030546
2 EX-31.1 fbrx-ex311_7.htm EX-31.1 20786
3 EX-31.2 fbrx-ex312_8.htm EX-31.2 20789
4 EX-32.1 fbrx-ex321_9.htm EX-32.1 8888
5 EX-32.2 fbrx-ex322_6.htm EX-32.2 8910
  Complete submission text file 0001564590-21-055083.txt   5985925

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA fbrx-20210930.xsd EX-101.SCH 38737
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE fbrx-20210930_cal.xml EX-101.CAL 32118
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE fbrx-20210930_def.xml EX-101.DEF 120224
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE fbrx-20210930_lab.xml EX-101.LAB 328021
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fbrx-20210930_pre.xml EX-101.PRE 238044
11 EXTRACTED XBRL INSTANCE DOCUMENT fbrx-10q_20210930_htm.xml XML 846469
Mailing Address 1124 W CARSON STREET MRL BUILDING 3-320 TORRANCE CA 90502
Business Address 1124 W CARSON STREET MRL BUILDING 3-320 TORRANCE CA 90502 (310) 618-6994
Forte Biosciences, Inc. (Filer) CIK: 0001419041 (see all company filings)

EIN.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38052 | Film No.: 211386709
SIC: 2834 Pharmaceutical Preparations